Comparison between Curis Lifesciences IPO and Katex Exim IPO.
Curis Lifesciences IPO is a SME Fixed Price IPO proposed to list at NSE SME while Katex Exim IPO is a SME Fixed Price proposed to list at BSE SME.
| Curis Lifesciences IPO | Katex Exim IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Finaax Capital Advisors Private Limited | Nirbhay Capital Services Pvt.Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | RS Wealth Management Private Limited | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Curis Lifesciences IPO is up to ₹26.14 Cr whereas the issue size of the Katex Exim IPO is up to ₹0.00 Cr. The final issue price of Curis Lifesciences IPO is ₹128.00 per share and of Katex Exim IPO is .
| Curis Lifesciences IPO | Katex Exim IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹120.00 per share | |
| Issue Price (Upper) | ₹128.00 per share | |
| Issue Price (Final) | ₹128.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | |
| Fresh Issue Size | 20,42,000 shares | 66,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹26.14 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 20,42,000 shares | 66,00,000 shares |
| Issue Size Total (Amount) | up to ₹26.14 Cr | up to ₹0.00 Cr |
Curis Lifesciences IPO opens on Nov 07, 2025, while Katex Exim IPO opens on . The closing date of Curis Lifesciences IPO and Katex Exim IPO is Nov 11, 2025, and , respectively.
| Curis Lifesciences IPO | Katex Exim IPO | |
|---|---|---|
| Anchor Bid Date | Nov 06, 2025 | |
| Issue Open | Nov 07, 2025 | |
| Issue Close | Nov 11, 2025 | |
| Basis Of Allotment (Tentative) | Nov 12, 2025 | |
| Initiation of Refunds (Tentative) | Nov 13, 2025 | |
| Credit of Share (Tentative) | Nov 13, 2025 | |
| Listing date (Tentative) | Nov 14, 2025 | |
| Anchor Lockin End date 1 | Dec 11, 2025 | |
| Anchor Lockin End date 2 | Feb 09, 2026 |
Curis Lifesciences IPO P/E ratio is 12.44, as compared to Katex Exim IPO P/E ratio of .
| Curis Lifesciences IPO | Katex Exim IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Curis Lifesciences Ltd.'s revenue increased by 38% and profit after tax (PAT) rose by 25% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.68 | 100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 68.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 12.44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹103.48 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 55.25 | 26.39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 27.83 | 13.67 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.96 | 3.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹10.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 37.62 | 23.37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Curis Lifesciences IPO Retail Individual Investors (RII) are offered 7,16,000 shares while in Katex Exim IPO retail investors are offered 7,16,000 shares. Qualified Institutional Buyers (QIB) are offered 4,08,000 shares in Curis Lifesciences IPO and in Katex Exim IPO.
| Curis Lifesciences IPO | Katex Exim IPO | |
|---|---|---|
| Anchor Investor Reservation | 6,09,000 shares | |
| Market Maker Reservation | 1,08,000 shares | 3,32,000 shares |
| QIB | 4,08,000 shares | |
| NII | 3,09,000 shares | |
| RII | 7,16,000 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 20,42,000 shares |
Curis Lifesciences IPO subscribed 74.39x in total, whereas Katex Exim IPO subscribed .
| Curis Lifesciences IPO | Katex Exim IPO | |
|---|---|---|
| QIB (times) | 96.17x | |
| NII (times) | 115.46x | |
| Big NII (times) | 142.74x | |
| Small NII (times) | 60.38x | |
| RII (times) | 44.28x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 74.39x |
